OmniAb (OABI) Share-based Compensation (2022 - 2026)
OmniAb (OABI) reported Share-based Compensation of $3.3 million for Q1 2026, down 19.4% year-over-year from $4.1 million in Q1 2025, and down 7.38% quarter-over-quarter from $3.6 million in Q4 2025.
OmniAb (OABI) Share-based Compensation (2022 - 2026) Analysis & Trends
OmniAb (OABI) has 5 years of Share-based Compensation data on file, last reported at $3.3 million in Q1 2026.
- Share-based Compensation for Q1 2026 came in at $3.3 million, down 19.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $15.0 million (down 24.7% YoY), and the FY2025 annual result was $15.8 million, down 26.4% from the prior year.
- Share-based Compensation retreated to $3.3 million in Q1 2026 per OABI's latest filing, from $3.6 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $6.5 million in Q2 2023 and troughed at $3.1 million in Q1 2022.
- A 5-year average of $4.9 million and a median of $5.3 million in 2022 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2023 and 2025: Share-based Compensation jumped 92.47% in 2023, then fell 29.52% in 2025.
- A 5-year view of Share-based Compensation shows it stood at $6.0 million in 2022, then dropped by 2.03% to $5.9 million in 2023, then declined by 13.67% to $5.1 million in 2024, then slipped by 29.52% to $3.6 million in 2025, then retreated by 7.38% to $3.3 million in 2026.
- Business Quant data shows OABI's Share-based Compensation at $3.3 million in Q1 2026, $3.6 million in Q4 2025, and $4.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 26.47 Mn |
| 10 | OmniAb | 294.96 Mn | 252.00 Mn | 14.41 Mn | 3.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.34 Mn |
| Mar 31, 2026 | 3.34 Mn |
| Dec 31, 2025 | 3.61 Mn |
| Dec 31, 2025 | 3.61 Mn |
| Sep 30, 2025 | 3.96 Mn |
| Sep 30, 2025 | 3.96 Mn |
| Jun 30, 2025 | 4.11 Mn |
| Jun 30, 2025 | 4.11 Mn |
| Mar 31, 2025 | 4.14 Mn |
| Mar 31, 2025 | 4.14 Mn |
| Dec 31, 2024 | 5.12 Mn |
| Dec 31, 2024 | 5.12 Mn |
| Sep 30, 2024 | 5.31 Mn |
| Sep 30, 2024 | 5.31 Mn |
| Jun 30, 2024 | 5.38 Mn |
| Jun 30, 2024 | 5.38 Mn |
| Mar 31, 2024 | 5.70 Mn |
| Mar 31, 2024 | 5.70 Mn |
| Dec 31, 2023 | 5.93 Mn |
| Dec 31, 2023 | 5.93 Mn |